checkAd

    Amarin - The Science Of Lipid Therapy (Seite 10)

    eröffnet am 03.01.14 20:10:32 von
    neuester Beitrag 06.03.24 15:20:48 von
    Beiträge: 1.834
    ID: 1.190.027
    Aufrufe heute: 0
    Gesamt: 155.456
    Aktive User: 0


    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 1
    • 10
    • 184

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 23.08.22 17:06:34
      Beitrag Nr. 1.744 ()
      Aus fachlicher Sicht finde ich die Beurteilung von Eicosapent-Ethyl zwar eindeutig zu negativ in der Darstellung der Fachpresse und unser IQWiG ohnehin nicht fair. Allerdings hat das Management von Amarin auch einen großen Fehler gemacht: Die Debatte um das „Mineral Oil“ = 2 x 2 g pharmazeutisches Paraffin hätte man viel früher offensiv angehen und durch eine neue Studie steuern bzw. die Kritiker wie Nissen widerlegen müssen.

      Warum macht man nicht eine Studie mit dem Endpunkt Biomarker für Herzinfarkt und Schlaganfall, bei der man 2 x 2 g Paraffin gegen 2 x 2 g echtes Placebo testet. Das wäre doch soooo einfach. Cholesterinwerte, CRP und andere Entzündungsparameter vor und nach 4 Wochen Therapie. Deepak Bhatt/Harvard, Hauptautor von REDUCE-IT, sieht das auf Nachfrage über Twitter auch so wie ich.

      Diese Studie könnte man kostengünstig umsetzen und hätte dann eine klare Aussage, um wie viel sich die für das Herz-Kreislauf-Risiko relevanten Parameter tatsächlich verändern oder nicht. Schwer vorstellbar, dass so wenig inertes Öl (geht hinten raus wie es vorne reinkommt) tatsächlich das Risiko der Placebo-Gruppe in REDUCE-IT relevant gesteigert haben soll, wenn dasselbe Paraffin in zahlreichen anderen Studien kaum Effekte hatte.

      Wer sagt das mal dem Amarin Management?
      Amarin | 1,305 $
      Avatar
      schrieb am 23.08.22 14:28:28
      Beitrag Nr. 1.743 ()
      Amarin
      Um bei den Fakten zu bleiben, Amarin wird weiterhin in den USA 350-400 Millionen US Dollar Umsatz machen und cash flow positiv arbeiten, EU durch deutsche Arroganz bzw. Unverschämtheit geschwächt, dafür England mit kritischer NICE voll an Board, damit ist nicht alles in der EU verloren!
      ROW, Canada boomt mit Vascepa und Partner Pfizer, China......

      Ich würde an Pfizer verkaufen, die haben mehr Marktmacht und know how....

      Jedoch kommt noch die Brave Studie Anfang nächsten Jahres mit Alzheimer und Vascepa, sollte die positiv sein, zurück zu den alten Hochs.......
      Amarin | 1,285 €
      Avatar
      schrieb am 23.08.22 13:37:06
      Beitrag Nr. 1.742 ()
      hab nachgelegt - volles Risiko
      Amarin | 1,285 €
      Avatar
      schrieb am 23.08.22 13:18:34
      Beitrag Nr. 1.741 ()
      Antwort auf Beitrag Nr.: 72.252.939 von Magnetfeldfredy am 23.08.22 11:11:39Was eine Rotze … die Fa. Bekommt seit Jahren nur Steine ? in den Weg geworfen …
      Amarin | 1,285 €
      Avatar
      schrieb am 23.08.22 11:11:39
      Beitrag Nr. 1.740 ()
      Amarin
      Das ist wohl der Grund:
      https://www.deutsche-apotheker-zeitung.de/news/artikel/2022/…

      für mich nicht nachvollziehbar, da in Großbritannien, Irland, Wales, die voller Erstattung und Verschreibung genehmigt wurde, da hat wohl der Teufel, Dr. Nissen seine Hände im Spiel und bringt das Mineralöl-Plabebo wieder ins Gespräch was immer schon Bullshit war, die Jelis Studie hatte überhaupt kein Placebo, entweder Statin alleine oder Statin + hochdosiertes EPA, Ergebnis: 19 % weniger Herzinfarkte, .....

      Die Deutschen sollen wohl nicht nur beim Duschen sparen sondern auch weiterhin ein super Produkt verwährt bleiben, scheiß Rot-Grün!

      662 ARS MEDICI 13 ■ 2007
      S T U D I E
      Die JELIS-Studie prüfte bei
      hypercholesterinämischen
      japanischen Patienten – die an
      sich schon grosse Mengen von
      Fisch verzehren – die Hypo-
      these, dass die Langzeitein-
      nahme von Eicosapentaen-
      säure (EPA) schwere Koronar-
      ereignisse verhüten kann.
      T H E L A N C E T
      Epidemiologische und klinische Evidenz
      deuten darauf hin, dass zwischen der
      langfristigen Einnahme von langketti-
      gen, mehrfach ungesättigten Fettsäuren,
      insbesondere Eicosapentaensäure (EPA)
      und Docosahexaensäure (DHA), und der
      durch eine koronare Herzkrankheit (KHK)
      bedingten Mortalität eine signifikante
      inverse Assoziation besteht. Diese hat
      zur Hypothese geführt, dass der Verzehr
      von Fisch oder von Fischöl vor tödli-
      chem Myokardinfarkt (MI) oder plötzli-
      chem Herztod schützen könnte. Heute
      sind Statine bei Hypercholesterinämie in
      der Primär- und Sekundärprävention
      fest etabliert. Die vorliegende Studie
      wollte prüfen, ob die EPA-Langzeitein-
      nahme zusätzlich zu dieser Standardthe-
      rapie zu einer Reduktion schwerer Koro-
      narereignisse führt.
      Methodik
      Die japanischen Autoren nahmen eine
      prospektive, randomisierte offene Be-
      handlungsstudie mit verblindeter End-
      punktevaluation vor. Bei den Teilneh-
      menden handelte es sich um 5859 Män-
      ner zwischen 40 und 75 Jahren sowie
      12 768 postmenopausale Frauen bis 75
      Jahre. Einschlusskriterium war ein Ge-
      samtcholesterin von 6,5 mmol/l, ent-
      sprechend einem LDL-Cholesterin von
      4,4 mmol/l.
      Alle Patienten erhielten entweder 10 mg
      Pravastatin (Selipran® oder Generika)
      oder 5 mg Simvastatin (Zocor® oder Ge-
      nerika) mit der Option zur Dosisverdop-
      pelung bei ungenügendem Ansprechen
      der Lipidwerte. Die eine Hälfte erhielt
      zusätzlich EPA (in der Schweiz z.B.:
      Burgerstein EPA-Kapseln Antistress, Ei-
      cosapen®, Epacaps®, Omega-3 Gisand® ,
      Omegaven®, OMEGA-Life®) in der sehr
      hohen Dosierung von dreimal 600 mg,
      jeweils nach den Mahlzeiten.
      Resultate
      Die Patienten wurden durchschnittlich
      über 4,6 Jahre verfolgt. 90 Prozent der
      Patienten nahmen entweder 10 mg Pra-
      vastatin oder 5 mg Simvastatin; die
      Compliance war in den verschiedenen
      Gruppen ähnlich (71–74%).
      586 Patienten (262 [2,8%] in der EPA-
      und 324 [3,5%] in der Kontrollgruppe)
      erreichten den zusammengesetzten pri-
      mären Endpunkt eines schweren Koro-
      narereignisses (plötzlicher Herztod, töd-
      licher und nicht tödlicher MI, andere
      nichttödliche Ereignisse wie unstabile
      Angina pectoris, Angioplastie, Stent oder
      Bypass). Dies entspricht einer relativen
      Reduktion von 19 Prozent (p = 0,011).
      Unter Behandlung sanken die LDL-Cho-
      lesterinwerte in beiden Behandlungs-
      armen um 25 Prozent. Der Serumcholes-
      terinwert war jedoch kein signifikanter
      Faktor bei der Risikoreduktion von
      schweren Koronarereignissen. In der
      EPA-Gruppe waren auch instabile An-
      gina pectoris und nichttödliche Koronar-
      ereignisse signifikant vermindert, hinge-
      gen bestand kein Unterschied für plötz-
      lichen Herztod und Koronartod. Bei
      Patienten mit einer positiven KHK-Ana-
      mnese brachte die EPA-Behandlung eine
      Eicosapentaensäure ver-
      hindert Koronarereignisse
      Ergebnisse der JELIS-Studie bei Patienten mit
      Hypercholesterinämie


      NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales

      Amarin Corporation plc
      July 13, 2022
      In this article:

      AMRN
      -18.99%

      Amarin Corporation plc
      Amarin Corporation plc

      -- Newly published final guidance by the National Institute for Health and Care Excellence (NICE) in the UK confirms its prior draft recommendation for the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]), controlled LDL-C between 1.04 mmol/L - 2.60 mmol/L and established cardiovascular disease (eCVD).1,2 --

      DUBLIN, Ireland and BRIDGEWATER, N.J., July 13, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that NICE has issued its final guidance recommending VAZKEPA® (icosapent ethyl) for reimbursement and use across the National Health Service (NHS) in England and Wales to help reduce the risk of major CV events in high-risk statin-treated patients with eCVD, at a price of £144.21 per 120 soft capsules (i.e. 30 day supply; the equivalent of approximately 171 EUR or 172 USD*).

      This announcement marks a major milestone for Amarin globally and in the UK, as following final guidance, all local NHS formularies in England and Wales will need to make VAZKEPA available within 90 and 60 days, respectively. Today’s final guidance also further supports the successful execution of Amarin’s European growth strategy, and the Company’s efforts to unlock the multi-billion-dollar revenue opportunities for the product outside of the U.S.**

      Karim Mikhail, president and chief executive officer of Amarin said, “Receiving this final guidance from NICE is a significant moment, as it is another important step in our international expansion. Our teams in Europe are working incredibly hard to ensure a successful launch of VAZKEPA, so we can help transform the lives of CV patients across the region and move closer to realizing our bold vision of reaching the day when heart disease is no longer a leading cause of death.”

      The publication of the final guidance supports the growing recognition of VAZKEPA’s clinical benefits. It is the last step in the NICE Health Technology Appraisal (HTA) process, used to assess the clinical benefits and cost-effectiveness of medicines and treatments in England to ensure the NHS uses its resources fairly and cost-effectively. Based on the collaborative relationship between the Welsh Government and the All-Wales Medicines Strategy Group (AWMSG), the final NICE guidance will also be implemented across the NHS in Wales, in line with the devolved powers of the Welsh Assembly.

      Commenting on today’s news, Laurent Abuaf, senior vice president and president, Amarin Europe said, “We have a once in a generation opportunity to transform the lives of cardiovascular patients across Europe, and today’s announcement regarding NICE’s final guidance will help us realize that mission in one of our key markets. Following the successful completion of the HTA assessment in the UK, and the positive reimbursement guidance, our local teams in every country in Europe will be inspired by how the UK will be prioritizing access to local health economies. Our teams in the UK will of course work tirelessly to make this medicine available across the whole territory in the coming months.”

      Off the back of this success, Amarin continues to drive forward reimbursement discussions in other major European markets and remains on track to receive pricing decisions in up to eight countries with plans to launch VAZKEPA in up to six European countries this year.
      Amarin | 1,285 €
      1 Antwort

      Trading Spotlight

      Anzeige
      Was die Börsencommunity nach Ostern auf keinen Fall verpassen willmehr zur Aktie »
      Avatar
      schrieb am 22.08.22 23:57:56
      Beitrag Nr. 1.739 ()
      Antwort auf Beitrag Nr.: 72.249.480 von TecFan11 am 22.08.22 21:03:43Dieses Teil kostet mich Nerven seit Jahren 🙄
      Amarin | 1,280 $
      Avatar
      schrieb am 22.08.22 21:03:43
      Beitrag Nr. 1.738 ()
      Habe ich irgendwelche schlechten Nachrichten übersehen? Massiver Abverkauf bei hohen Stückzahlen....
      Amarin | 1,230 $
      1 Antwort
      Avatar
      schrieb am 15.08.22 15:26:47
      Beitrag Nr. 1.737 ()
      Amarin
      Die unterbewerteste Biotechaktie in meinen Augen, Pfizer freut sich auf bilige Übernahme in den nächsten 6-12 Monaten für 10-15 US Dollar, Alex Denner und Magnetfeldfredy wissen es:


      Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress

      Amarin Corporation plc
      Mon, August 15, 2022 at 2:00 PM
      In this article:

      AMRN
      +2.48%
      Watchlist
      Fair Value Estimateyahoo plus badge
      OvervaluedSee why

      Amarin Corporation plc
      Amarin Corporation plc

      DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA (icosapent ethyl) in specific patient subgroups at increased risk of a cardiovascular (CV) event from the landmark REDUCE-IT® cardiovascular outcomes trial have been accepted for presentation at the European Society of Cardiology (ESC) Congress, both online and onsite in Barcelona, August 26-29, 2022.

      The accepted abstracts include a Late-Breaking Science presentation on reduction of ST-segment Elevation MI with VASCEPA from the REDUCE-IT trial. These and other new findings will be presented by a variety of international academic collaborators based on research or analyses supported by Amarin.

      Featured Amarin-supported abstracts to be presented at ESC Congress 2022 include:

      Late-Breaking Science Presentation

      Session: Latest science in primary and secondary prevention and environmental health
      “Significant Reduction in ST-Elevation MI with Icosapent Ethyl in REDUCE-IT”
      Deepak L. Bhatt, Robert P. Giugliano, Ph. Gabriel Steg, Michael Miller, et al.

      – Available August 26 at 2:18 p.m. CEST (8:18 a.m. EST) in room: Dali

      Abstract Sessions Presentation

      Session: Optimal risk factor therapy in high risk patients
      “Icosapent Ethyl Diminishes CVD Risk in Smokers: REDUCE-IT Smoking”
      Michael Miller, Deepak L. Bhatt, Ph. Gabriel Steg, Eliot A. Brinton, et al.

      – Available August 28 at 11:50 a.m. CEST (5:50 a.m. EST) in room: Science Box 3

      “We are pleased to support these Late Breaking Science and Oral Presentations at the upcoming ESC Congress being held later this month,” said Nabil Abadir, MB. CH.B., SVP, Chief Medical Officer and Head of Global Medical Affairs, Amarin. “These data continue to underscore the clinical and therapeutic utility and value of VASCEPA/VAZKEPA and continue to validate the clinical outcomes shown in the overall REDUCE-IT trial. As we know, REDUCE-IT demonstrated the clear risk reduction benefits of icosapent ethyl in reducing cardiovascular events among patients most at risk for cardiovascular disease including those with previous cardiovascular events, such as myocardial infarction (MI) or stroke. We are proud of the continued work that is being done to further demonstrate the proven efficacy of VASCEPA in cardiovascular risk reduction while providing support to investigators to explore other ways in which VASCEPA can potentially help patients and impact public health.”

      About Amarin
      Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.

      About Cardiovascular Risk
      Cardiovascular disease is the number one cause of death in the world. In the United States alone, cardiovascular disease results in 859,000 deaths per year.1 And the number of deaths in the United States attributed to cardiovascular disease continues to rise. In addition, in the United States there are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds). Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. In aggregate, in the United States alone, there are more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, 1 every 13 seconds.

      Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient’s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.2 Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.3,4,5

      About REDUCE-IT®
      REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort).

      REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.6 The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.7 The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.8 These and other publications can be found in the R&D section on the company’s website at www.amarincorp.com.

      About VASCEPA®/VAZKEPA® (icosapent ethyl) Capsules

      VASCEPA capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl, a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first and only drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk after statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over 18 million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, icosapent ethyl is approved and sold in Canada, Lebanon, Germany and the United Arab Emirates. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA (icosapent ethyl) was granted in Great Britain. The Great Britain Marketing Authorization for VAZKEPA applies to England, Scotland and Wales.

      United States
      Indications and Limitation of Use

      VASCEPA is indicated:

      As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and

      established cardiovascular disease or

      diabetes mellitus and two or more additional risk factors for cardiovascular disease.

      As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

      The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

      Important Safety Information

      VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.

      VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.

      It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.

      VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.

      Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).

      Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).

      Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

      Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.

      FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.

      Europe
      For further information about the Summary of Product Characteristics (SmPC) for VAZKEPA® in Europe, please click here.
      Globally, prescribing information varies; refer to the individual country product label for complete information.

      Forward-Looking Statements
      This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about the potential for VASCEPA (marketed as VAZKEPA in Europe); beliefs about icosapent ethyl (IPE)’s role concerning patients suffering from cardiovascular disease (CVD) and impacts on the risk of heart attack, stroke or other fatal or non-fatal cardiovascular events for patients who suffered a prior heart attack, as well as general beliefs about the safety and effectiveness of VASCEPA. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2021. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. Availability of Other Information About Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

      Availability of Other Information About Amarin
      Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

      Amarin Contact Information

      Investor Inquiries:
      Investor Relations
      Amarin Corporation plc
      In U.S.: +1 (908) 719-1315
      IR@amarincorp.com

      Media Inquiries:
      Communications
      Amarin Corporation plc
      In U.S.: +1 (908) 892-2028
      PR@amarincorp.com

      AMARIN, REDUCE-IT, VASCEPA and VAZKEPA are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.


      Zacks
      Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics
      Amarin | 1,615 €
      Avatar
      schrieb am 12.08.22 11:45:59
      Beitrag Nr. 1.736 ()
      Mal schauen, ob das Volumen weiter ansteigt - ich gehe davon aus, das die 2 Dollar schnell erreicht werden, spannend wird die Zone zwischen 2,03 und 2,64, danach wäre das gap aus dem Mai geschlossen.
      Amarin | 1,545 €
      Avatar
      schrieb am 12.08.22 10:16:57
      Beitrag Nr. 1.735 ()
      Amarin
      In den letzten Tagen hat sich bei steigendem Volumen jemand eingekauft, Alex Dennner erhöht für buyout?
      Amarin | 1,545 €
      • 1
      • 10
      • 184
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      +0,31
      -1,06
      +0,40
      +0,04
      +0,06
      -0,01
      -1,30
      +1,09
      +0,32
      -17,51
      25.03.24 · globenewswire · Amarin
      29.02.24 · globenewswire · Amarin
      15.02.24 · globenewswire · Amarin
      23.01.24 · wO Chartvergleich · Canadian Imperial Bank of Commerce
      22.01.24 · globenewswire · Amarin
      10.01.24 · globenewswire · Amarin
      12.11.23 · globenewswire · Amarin
      01.11.23 · globenewswire · Amarin
      31.10.23 · globenewswire · Amarin
      26.10.23 · globenewswire · Amarin
      Amarin - The Science Of Lipid Therapy